Our People
InVivium Capital Team
Michael Liang, Ph.D.
Managing Partner
Email
Michael Liang, Ph.D.
Managing Partner
Michael Liang, Ph.D. is a Managing Partner with InVivium Capital. Previously, Mike spent 16 years as a Partner with Baird Capital, overseeing healthcare investments. Prior to joining Baird Capital, Mike was a healthcare investor with Advent Venture Partners (London, U.K.) and before that served in an operating role as a Director of R&D at Cortek, a spinal orthopedics company. Mike serves on the Board of Directors of Onchilles Pharma and was also previously a Board Member of Alto Neuroscience (NYSE: ANRO), GreenLight Biosciences (NASDAQ: GRNA), Interlace Medical (sold to Hologic), OncoHealth (sold to Arsenal Capital Partners), Veniti (sold to Boston Scientific), and a board observer of TomoTherapy (NASDAQ: TOMO, sold to Accuray). Mike also recently served on the Board of Directors of AiCure, Jumpcode Genomics, NeoChord and Zurex Pharma, and was a Board Observer for Saranas and Virtual Incision. Mike received a B.S. in bioorganic chemistry from the University of California, Berkeley, completed a Ph.D. in biophysical chemistry from Stanford University, and conducted a postdoctoral fellowship at Harvard University.
Amy Len Kobe
Partner
Email
Amy Len Kobe
Partner
Amy Len Kobe is a Partner with InVivium Capital. Amy was previously a Principal with Baird Capital where she led investments on the Healthcare team. Amy is currently a Board Observer for Virtual Incision and Onchilles Pharma. She previously served on the board of directors of Cala Health, Saranas and Virtual Incision and was an observer for Jumpcode, Upfront Healthcare, OncoHealth and AiCure. Prior to Baird Capital, Amy was a venture investor with Baxter Healthcare, focused on medical devices, monitoring, and data analytics opportunities. She was also previously with Healthbox, focused on tech-enabled products and services. Amy began her career with roles at McKinsey & Company and Genentech. Amy received a B.S. and M.S. in chemical engineering from Stanford University and an MBA from Kellogg School of Management. She is also a member of the Economic Club of Chicago, where she serves on the Young Leaders Committee.
Christopher Cox
Partner
Christopher Cox
Partner
Christopher Cox, J.D., is a Partner with InVivium Capital. Chris is currently the CEO of Lightswitch Capital, a private equity firm focused on biotechnology and was previously Vice Chairman of BrightSphere, a NYSE-listed asset manager with over $240 billion in assets. He was also previously a corporate associate at Weil, Gotshal & Manges LLP. Chris serves on the board of Alto Neuroscience and is also a board member of the Richard Nixon Foundation, the American University of Afghanistan, the Command and General Staff College Foundation and the Sunswyck Foundation. Chris received an A.B. in politics from Princeton University and a J.D. from NYU School of Law.
Alyse Passaglia
Vice President of HR & Operations
Email
Alyse Passaglia
Vice President of HR & Operations
Alyse Passaglia is a Vice President of HR & Operations with InVivium Capital. Previously, Alyse spent 11 years at GCM Grosvenor, in both the Fund Accounting department and as a member of the Human Resources team. Alyse received a B.S. in Education from Illinois State University.
Shahryar Oveissi
Operating Partner
Email
Shahryar Oveissi
Operating Partner
Shahryar Oveissi is an Operating Partner with InVivium Capital. He is an investor with experience across biotechnology, sustainability, carbon markets, and agriculture. Previously, Shahryar was a Director at Diomics Corporation, a biotechnology company focused on stem cell-based therapies, and a Partner at Rose Capital, an agriculture investment fund. Prior to that, he spent eight years as an Operating Partner at Pegasus Capital Advisors, a $2 billion AUM private equity firm. Shahryar serves on the board of BioSource Feeds and was previously a board member of Six Senses Hotels Resorts & Spas, ZeroBase Energy, and Todd English Enterprises. He is also an advisor to GATC Health, a life sciences company focused on drug discovery and validation using a proprietary AI platform. Shahryar received a B.S. in Information Systems and International Business from the NYU Stern School of Business.
Christine Neipert, J.D., Ph.D.
IP Advisor
Christine Neipert
J.D., Ph.D., IP Advisor
Christine Neipert has over 15 years of experience in intellectual property, healthcare reimbursement, and technology commercialization. She has worked on both the entrepreneurial side, helping lead multiple funding rounds for companies such as Walden Biosciences and STAT3 Therapeutics, and on the venture capital side, assisting with target investment diligence. Christine’s expertise encompasses IP strategy and due diligence, as well as the development of commercialization pathways for innovative healthcare technologies, ensuring successful market entry and sustainability for emerging companies. She earned her PhD in Chemistry from the University of South Florida and her JD from Franklin Pierce Law Center.
